European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Amyloidosis: Perspectives from Nephrology and Internal Medicine

Submitted by claudine.buys on 13 October 2026 - 15:33

To register for this webinar, please click below:
Amyloidosis: Perspectives from Nephrology and Internal Medicine

Description
The Young Nephrologists’ Platform (YNP) and EFIM Young Internists are pleased to invite you to our upcoming webinar on Amyloidosis: Perspectives from Nephrology and Internal Medicine, taking place on Wednesday, 4 November from 17:00 to 18:00 CET.

Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 12 October 2026 - 16:00

Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 12 October 2026 - 15:48

Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Roclanda, latanoprost / netarsudil, Date of authorisation: 07/01/2021, Revision: 13, Status: Authorised

Submitted by Anonymous (not verified) on 12 October 2026 - 15:46

Human medicines European public assessment report (EPAR): Roclanda, latanoprost / netarsudil, Date of authorisation: 07/01/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Date of authorisation: 06/06/2025, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 12 October 2026 - 15:42

Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Date of authorisation: 06/06/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 12 October 2026 - 15:35

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 17/06/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 12 October 2026 - 15:12

Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 17/06/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 30, Status: Authorised

Submitted by Anonymous (not verified) on 12 October 2026 - 15:05

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 30, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More